BioMarin Pharma (NASDAQ: BMRN) reported Q3 GAAP EPS of ($0.07), $0.05 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $334.1 million versus the consensus estimate of $349.59 million.

GUIDANCE:

BioMarin Pharma sees FY2017 revenue of $1.29-1.32 billion, versus the consensus of $1.31 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.